rs377294947
Variant summary
Our verdict is Pathogenic. The variant received 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000136.3(FANCC):c.65G>A(p.Trp22*) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000372 in 1,614,018 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000136.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- Fanconi anemia complementation group CInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), G2P, Myriad Women’s Health
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- colorectal cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- malignant pancreatic neoplasmInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- ovarian cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- prostate cancerInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 16 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| FANCC | NM_000136.3 | c.65G>A | p.Trp22* | stop_gained | Exon 2 of 15 | ENST00000289081.8 | NP_000127.2 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152194Hom.: 0 Cov.: 32 show subpopulations
GnomAD4 exome AF: 0.00000205 AC: 3AN: 1461824Hom.: 0 Cov.: 31 AF XY: 0.00000413 AC XY: 3AN XY: 727218 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152194Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74338 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Fanconi anemia complementation group C Pathogenic:5
Curator: Arleen D. Auerbach. Submitters to LOVD: Arleen D. Auerbach, Daniela Pilonetto, Johan de Winter. -
Variant summary: The FANCC c.65G>A (p.Trp22X) variant results in a premature termination codon, predicted to cause a truncated or absent FANCC protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.67delG/p.Asp23fsX23, c.1642C>T/p.Arg548X). One in silico tool predicts a damaging outcome for this variant. This variant was found in 1/121148 control chromosomes at a frequency of 0.0000083, which does not exceed the estimated maximal expected allele frequency of a pathogenic FANCC variant (0.0017678). This variant has been reported in at least three patients with Fanconi Anemia. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic/likely pathogenic. Taken together, this variant is classified as pathogenic. -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
- -
- -
Fanconi anemia Pathogenic:2
- -
This sequence change creates a premature translational stop signal (p.Trp22*) in the FANCC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCC are known to be pathogenic (PMID: 17924555). This variant is present in population databases (rs377294947, gnomAD 0.008%). This premature translational stop signal has been observed in individual(s) with clinical features of Fanconi anemia (PMID: 8844212, 28717661). ClinVar contains an entry for this variant (Variation ID: 188926). For these reasons, this variant has been classified as Pathogenic. -
FANCC-related disorder Pathogenic:1
The FANCC c.65G>A variant is predicted to result in premature protein termination (p.Trp22*). This variant has been reported in the homozygous state in at least two patients with Fanconi anaemia (Gibson et al. 1996. PubMed ID: 8844212; Ameziane et al. 2008. PubMed ID: 17924555). This variant is reported in 0.011% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/9-98011509-C-T). Nonsense variants in FANCC are expected to be pathogenic. This variant is interpreted as pathogenic. -
not provided Pathogenic:1
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 34774576, 29922827, 17924555, 12670332, 28717661, 8844212, 27832981, Rodriguez2005[article]) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.W22* pathogenic mutation (also known as c.65G>A), located in coding exon 1 of the FANCC gene, results from a G to A substitution at nucleotide position 65. This changes the amino acid from a tryptophan to a stop codon within coding exon 1. This alteration has been identified in the homozygous state in several patients with Fanconi Anemia (Gibson RA et al. Hum Mutat. 1996;8:140-8; Ameziane N et al. Hum Mutat. 2008 Jan;29:159-66; Pilonetto DV et al. Mol Genet Genomic Med. 2017 Jul;5:360-372). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at